To get a better overall view of whether hybrid markers might be useful, we tested plasma samples from 60 adenoma patients (30 larger adenomas and 30 early adenomas) and 60 CRC patients (11 I, 17 IIa and 2 IIb, 6 IIIa, 10 IIIb, 5 IIIc and 9 IV stages) using proteomic, IgG-complex and Lewis X detection. The gene discussed is FUT4; the disease is adenoma.